Country: Canada
Language: English
Source: Health Canada
GLUCAGON (RECOMBINANT DNA ORIGIN)
ELI LILLY CANADA INC
H04AA01
GLUCAGON
1MG
KIT
GLUCAGON (RECOMBINANT DNA ORIGIN) 1MG
INTRAMUSCULAR
1 ML
Schedule D
GLYCOGENOLYTIC AGENTS
Active ingredient group (AIG) number: 0142861001; AHFS:
CANCELLED POST MARKET
2023-12-18
GLUCACON (rDNA Origin) Product Monograph Page 1 of 32 PRODUCT MONOGRAPH GLUCAGON GLUCAGON FOR INJECTION, RDNA ORIGIN 1 MG GLUCAGON PER VIAL Sterile Lyophilized Powder and Diluent Hyperglycemic Agent © Eli Lilly Canada Inc. 3650 Danforth Avenue Toronto, Ontario M1N 2E8 1-888-545-5972 Date of Approval: July 9, 2012 www.lilly.ca Submission Control No: 139332 GLUCACON (rDNA Origin) Product Monograph Page 2 of 32 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 3 SUMMARY PRODUCT INFORMATION .............................................................................. 3 INDICATIONS AND CLINICAL USE ................................................................................... 3 CONTRAINDICATIONS ......................................................................................................... 4 ADVERSE REACTIONS ......................................................................................................... 6 DRUG INTERACTION ............................................................................................................ 8 DOSAGE AND ADMINISTRATION ..................................................................................... 9 OVERDOSAGE ...................................................................................................................... 11 ACTION AND CLINICAL PHARMACOLOGY .................................................................. 12 STORAGE AND STABILITY ............................................................................................... 13 DOSAGE FORMS, COMPOSITION AND PACKAGING ................................................... 13 PART II: SCIENTIFIC INFORMATION .............................................................................. 14 PHARMACEUTICAL INFORMATION ............................................................................... 14 CLINICAL TRIALS ........................................................................................................... Read the complete document